Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Skinvisible (SKVI) Shares Issued (2016 - 2025)

Skinvisible (SKVI) has disclosed Shares Issued for 5 consecutive years, with $24780.0 as the latest value for Q1 2025.

Quarterly Shares Issued changed N/A to $24780.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $24780.0 through Dec 2025, down 69.41% year-over-year, with the annual reading at $24780.0 for FY2025, 62.45% down from the prior year.
Shares Issued hit $24780.0 in Q1 2025 for Skinvisible, down from $30000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $30000.0 in Q4 2024 to a low of $1000.0 in Q3 2024.